We previously reported on the development of a water soluble formulation of the cell wall skeleton of BCG (BCG-CWS), a major immune active center of BCG, by encapsulating it into a nanoparticle (CWS-NP). The CWS-NP allowed us to clarify the machinery associated with the BCG mediated anti-bladder tumor effect, especially the roles of bladder cancer cells and dendritic cells (DCs) in the initial step, which remains poorly understood. We show herein that the internalization of BCG-CWS by bladder cancer cells, but not DCs, is indispensable for the induction of an antitumor effect against bladder cancer. Tumor growth was significantly inhibited in mice that had been inoculated with mouse bladder cancer (MBT-2) cells containing internalized BCG-CWS. On the other hand, the internalization of BCG-CWS by DCs had only a minor effect on inducing an antitumor effect against MBT-2 tumors. This was clarified for the first time by using the CWS-NP. This finding provides insights into our understanding of the role of bladder cancer cells and DCs in BCG therapy against bladder cancer.
Intravesical Bacillus Calmette-Guérin (BCG) therapy has been clearly shown to be effective against superficial bladder cancer and carcinoma in situ [1, 2] , and is one of the strongest and most successful types of immunotherapy. Although this form of treatment is quite effective, serious side-effects associated with the use of live mycobacteria can occur [3] . Thus, a non-infectious immunotherapeutic drug instead of live BCG would be highly desirable. The cell wall skeleton of BCG (BCG-CWS), the main immune active center of BCG [4] , is a potent candidate. BCG-CWS is a huge assembly of peptidoglycans, arabinogalactans and mycolic acids [5] . It is known to be an adjuvant that is recognized by the toll-like receptors (TLR) 2 and 4 that are located on the cell surface, and induces anti-tumor immunity in an animal model and in humans [4, [6] [7] [8] . However, it is quite difficult to formulate a suitable water-soluble drug without the BCG-CWS undergoing aggregation, because BCG-CWS is insoluble in both aqueous and non-aqueous solvent.
We recently succeeded in developing, for the first time, a water soluble formulation of BCG-CWS by encapsulating BCG-CWS into nanoparticles using the liposome evaporated via emulsified lipid (LEEL) method [9] . The nanoparticle encapsulating BCG-CWS (CWS-NP) was highly uniform and could be easily dispersed without any detectable aggregation. CWS-NP efficiently delivered BCG-CWS into cells and showed significant anti-bladder tumor effects in mouse bearing bladder tumors and in a rat with naturally developed bladder cancer. Our success is significant in two way. One is that CWS-NP is a potent candidate for new immunotherapeutic drug against bladder cancer.
The second is that CWS-NP could be used better understand how BCG is involved in the anti-bladder tumor effect. Despite nearly four decades of clinical use, the mechanism of BCG therapy is still under investigation [10] . Because BCG is composed of many components, BCG infections can induce complicated responses. As a result, BCG components should be used for clarifying the machinery associated with BCG therapy. Although an immune response against BCG components in vitro using peripheral blood mononuclear cells has been demonstrated [11] , a definitive understanding of the mechanism of BCG therapy is not available. The reason for this is that it is currently not possible to deliver the main immune active component of BCG to cells in an efficient manner. That is, there is no technology for delivering BCG components, other than the use of live BCG. Our earlier report, however, indicates that it is quite possible to efficiently deliver BCG components, similar to live BCG. Our approach to this problem promises to clarify the machinery associated with the BCG mediated anti-bladder tumor effect at the molecular level by using CWS-NP.
Immune cells, especially antigen presenting cells (APCs), urothelial cells and bladder cancer cells are all present in the bladders of bladder cancer patients. Although it is unclear which cells initiate the development of anti-bladder immunity after interaction with the instilled BCG, it is likely that bladder cancer cells are the initiators, based on the following body of evidence. The induction of an effective anti-bladder tumor effect appears to require live BCG, but not heat-killed BCG [12, 13] . This fact indicates that cells need to be invaded in order to achieve an effective anti-bladder tumor effect.
Moreover, bladder cancer cells are exposed to the lumen of the bladder, because such cells are usually less differentiated, less polarized, exhibit a diminished expression of extracellular proteins and contain a minimal mucin layer [14] . That is, BCG can easily gain access to bladder cancer cells compared to urothelial cells. Interestingly, BCG-treated bladder cancer cells upregulate the expression of major histocompatibility complex (MHC) class II and the intracellular adhesion molecule 1 (ICAM-1), and produce cytokines, along with APCs [10] . Therefore, we hypothesized that the internalization of BCG-CWS by bladder cells is important for the initiation of anti-bladder tumor immunity.
In this study, we investigated the role of bladder cancer cells and DCs in terms of the internalization of BCG-CWS in the initiation of the anti-bladder tumor effect by using CWS-NP (Fig.  1a) . We designed an experimental scheme to investigate the role of internalization of BCG-CWS by bladder cancer cells and DCs in anti-bladder tumor effects in vivo (Fig. 1b) . Consequently, we were able to determine which specific cell-type is indispensable for the initiation of the anti-bladder tumor effect by using CWS-NP. 
Materials and Methods

Materials
Egg phosphatidylcholine (EPC) was purchased from NOF Corporation (Tokyo, Japan).
phosphoethanolamine (NBD-DOPE) was purchased from AVANTI Polar Lipids Inc. Stearylated octaarginine (STR-R8) was synthesized by KURABO. BCG-CWS (SMP-105) was generously provided from MBR Co., Ltd. SMP-150' starting raw material is a killed BCG (Tokyo 172 strain) which strain can only be supplied by Japan BCG Laboratory.
Preparation of CWS-NP
CWS-NP was prepared by the LEEL method, as described previously [9] . Briefly, Diameter, polydispersity index and zeta-potential was measured by a ZETASIZER Nano (ZEN3600, Malvern Instruments). The diameter, polydispersity index and zeta-potential of the CWS-NP were 173±8 nm, 0.241±0.02 and 41±1 mV.
Animal
C3H/HeN mice (female, 8-10 weeks) were obtained from Japan SLC, Inc (Sizuoka, Japan).
Experiments using mice were approved by the Pharmaceutical Science Animal Committee of Hokkaido University.
Preparation of bone marrow derived dendritic cells (BMDCs) of mice
BMDCs were prepared as previously reported [15, 16] . Briefly, bone marrow cells of C3H/HeN (female, 8-10 weeks) mice were cultured for 4 hours in RPMI1640 medium containing 10 mM HEPES, 50 µM 2-mercaptoethanol, 1 mM sodium pyruvate, 100 U/ml penicillin-streptomycin and 10% fetal bovine serum (FBS). Non-adherent cells were collected and cultured in the same medium supplemented with 10 ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF) (R&D systems, Basel, Switzerland). On day 2 and 4, non-adherent cells were removed and adherent cells were cultured in fresh medium containing 10 ng/ml GM-CSF. On day 6, non-adherent and loosely adherent cells were used as immature BMDCs.
Internalization of CWS-NP into MBT-2 cells or BMDCs
MBT - were then washed twice and were further incubated in RPMI1640 medium for 1 hour. After harvesting, the fluorescent intensity in the cells was measured by flow cytometry (Gallios, Beckman Coulter, Brea, CA) and was then analyzed using the Kaluza software package (Beckman Coulter, Brea, CA).
Cell growth of MBT-2 cells
MBT-2 cells (5×10 6 ) internalizing CWS-NP or NP w/o CWS were seeded in 35 mm dish and were cultured. After 3 days, the cells were re-seeded in 100 mm dish and were further cultured for 2 days. After harvesting the cells, the cells were stained with trypan blue and the number of live cells was counted. Tumor volume was calculated by the following formula: (major axis × minor axis 2 ) × 0.52. 
Antitumor effect
Histological analysis of MBT-2 syngraft tumor tissue
Statistical analysis
Comparisons between multiple treatments were made by one-way analysis of variance, followed by Tukey-Kramer test. The unpaired t-test was used to compare the results for the two treatments. In the case of the comparison of tumor volumes, the two-way repeated analysis of variance was used, followed by Tukey-Kramer test. A P value of <0.05 was considered to be a significant difference.
Results
Direct cytotoxicity of BCG-CWS against MBT-2 cells
It has been reported that the exposure of BCG to bladder cancer cells resulted in a decreased cell growth and the induction of cell death [17] [18] [19] . 
Effect of internalization of BCG-CWS by MBT-2 cells on antitumor effect
In a previous report, tumor growth was significantly inhibited in a group of mice that were inoculated with MBT-2 cells mixed with CWS-NP, compared to that of mice inoculated with MBT-2 cells only [9] . In this experimental design (Case 1 in Fig. 1b (Fig. 3a) .
The CWS-NP was taken up by 96.7% of the MBT-2 cells (Fig. 3b) . Thus, these results clearly show that MBT-2 cells internalize sufficient CWS-NP before inoculation into mice.
Mice Values are the means ± SEM (n=5-8, *P<0.05, **P<0.01).
Effect of internalization of BCG-CWS by immune cells on antitumor effect
To investigate the influence of immune cells on the antitumor effect, we subcutaneously inoculated mice with MBT-2 cells and subcutaneously injected CWS-NP (CWS-NP/s.c.) or NP w/o CWS (NP w/o CWS/s.c.) in a different location on the back of the same mouse (Case 3 in Fig. 1b) .
CWS-NP appear to be internalized by only subcutaneous immune cells, including DC, because CWS-NP
was subcutaneously injected at some distance from the point where the MBT-2 cells were inoculated. As a result, the subcutaneous injection of CWS-NP resulted in no inhibition of MBT-2 tumor growth (Fig.   4 ). The antitumor effect was drastically decreased compared to the mice that received CWS-NP/mix or CWS-NP/wash.
In addition, we prepared BMDC and subcutaneously inoculated mice with the MBT-2, followed by the subcutaneous injection of BMDCs incorporating CWS-NP in a different location on the back of the same mouse (Case 4 in Fig. 1b) . CWS-NP was internalized only by BMDCs. We also examined the internalization of CWS-NP by BMDCs before injecting the mice with washed cells. NBD-labeled CWS-NP was incubated with BMDCs and the fluorescent intensity in the BMDCs were then measured.
The fluorescent intensity of BMDCs was drastically increased after the CWS-NP treatment (Fig. 5a ).
The CWS-NP was taken up by 97.5% of the BMDCs (Fig. 5b) . Thus, these results clearly show that the BMDCs internalize sufficient CWS-NP before inoculation into mice.
The administration of BMDCs showed a significant antitumor effect (Fig. 5c ). However, no difference regarding for the antitumor effect between the administration of BMDCs internalizing CWS-NP and the administration of non-treated BMDCs was not observed (Fig. 5c ). Thus, these data suggest that the antitumor effect mediated by CWS-NP is not due to the direct interaction of BCG-CWS with subcutaneous immune cells or DCs. (Fig. 6a and Table) .
Moreover, the infiltration of white blood cells (WBC) into tumor tissue was observed in the case of CWS-NP/mix, CWS-NP/wash and CWS-NP/s.c. at a comparable level ( Fig. 6b and Table) . We also counted the number of WBC that had infiltrated into tumor tissues (Table) . In the case of CWS-NP/mix, CWS-NP/wash and CWS-NP/s.c., numerous WBC were found to have infiltrated into the tumor tissue.
The infiltrated WBCs included macrophages, lymphocytes, neutrophils, eosinophils and mast cells (Table) . These observations suggest that CWS-NP induces the infiltration of immune cells into tumor tissue. 
Discussion
Some reports of in vitro experiments showed that the exposure of BCG to bladder cancer cells decreased cell growth and induced cell death [17] [18] [19] . However, this type of cytotoxicity was induced only with very high ratios of BCG to bladder cancer cells. These ratios are unlikely to be found in a clinical setting. In addition, no evidence currently exists that the direct cytotoxicity of BCG occurs in vivo. The cytotoxicity of BCG against bladder cancer continues to be a controversial issue. The growth of MBT-2 cells was not inhibited by treatment with CWS-NP under our experimental conditions (Fig. 2) , although CWS-NP was efficiently taken up by MBT-2 cells within 1 hour [9] . This result indicates that the internalization of CWS-NP by MBT-2 cells had no effect on cell growth. The experimental conditions for CWS-NP exposure to MBT-2 cells were common both in vitro and in vivo. Hence, we conclude that the direct cytotoxicity by CWS-NP is not associated with the anti-bladder tumor effect mediated by CWS-NP. Figure 3c clearly shows that the internalization of BCG-CWS by bladder tumor cells substantially contributes to the induction of the anti-bladder tumor effect. BCG-CWS does not appear to be involved in the process of attachment to bladder cancer cells, because the BCG-CWS in CWS-NP is covered with lipid layers and is located in an inner phase of the lipid nanoparticle. CWS-NP is taken up by bladder cancer cells, which is mediated by octaarginine, which is present on the surface of CWS-NP [9] . Thus, the processes that occur after cellular uptake appear to be involved in the anti-bladder tumor effect. BCG-CWS may be degraded in the lysosomal compartments, because the CWS-NP localized in acidic compartments after being taken up by MBT-2 cells [9] . It has been reported that murine bladder carcinoma cells present BCG to specific CD4+ T cells that are derived from bladder-draining lymph nodes following intravesical BCG administration [20] . Glucose monomycolate, a glycolipid derived from Mycobacteria, is present on the CD1 molecule and the presentation induces antigen specific T cell responses [21] [22] [23] . It is likely that the anti-bladder tumor effect was induced by presenting the component of degraded BCG-CWS to T cells. However, antigens that are present on T cells in the context of BCG or BCG-CWS for bladder cancer have not been identified. Further studies will be needed in this area. Fig. 1b) showed no anti-bladder tumor effect (Fig. 4) , suggesting that BCG-CWS must associate with MBT-2 cells in order to induce the anti-bladder tumor effect. This result is consistent with the requirement of BCG-mediated antitumor effects [24] . Moreover, the administration of DCs internalizing BCG-CWS failed to enhance the anti-bladder tumor effect, although DC administration enhanced the anti-bladder tumor effect (Fig. 5c ). This result clearly indicates that the internalization of BCG-CWS by DCs is not required for the induction of the anti-bladder tumor effect.
CWS-NP/s.c. (Case 3 in
On the other hand, it is known that BCG-CWS activates DC, resulting in an enhancement in the effectiveness of cancer immunotherapy [25] . The question arises as to why the BMDCs exposed with CWS-NP failed to enhance an anti-bladder tumor effect. When delivered by CWS-NP, BCG-CWS did not appear to be involved in the binding step to DCs along with the case of MBT-2 cells. BCG-CWS appear to elude recognition by TLRs on the cell surface. As a result, it is likely that the DC activation by BCG-CWS did not occur. Consequently, this suggests that BCG-CWS internalized by DCs has no effect on the initiation of an anti-bladder tumor effect.
The present possible mechanism responsible for the anti-bladder tumor effect mediated by live BCG is briefly the follows [10] . For the details, see the cited review. BCG attaches to urothelial cells or bladder cancer cells and is then internalized by them. DCs may also be taken up and process live BCG. (Table) . It is likely that the number of neutrophils were increased in the groups of CWS-NP/mix and CWS-NP/wash, although these differences did not reach the level of statistical significance. However, further investigations regarding the involvement of neutrophil is clearly called for. In addition, BCG and CWS-NP were taken up by bladder cancer cells via a similar pathway. It was recently reported that BCG is taken up by bladder cancer cells via macropinocytosis [30] . In the case of CWS-NP, macropinocytosis is involved in its uptake by bladder cancer cells [9] . Therefore, our findings provide support for how BCG initiates anti-bladder tumor immune responses.
That is, the invasion of live BCG into bladder cancer cells, but not DCs, initiates development of an anti-bladder tumor effect in BCG therapy.
The findings reported herein provide a rational mechanism for the initiation of the anti- 
